Effects of Atypical Versus Conventional Antipsychotics on the Prevalence of Tardive Dyskinesia

This study has been completed.

Sponsors and Collaborators:	National Institute of Mental Health (NIMH) Yale University
Information provided by:	National Institute of Mental Health (NIMH)
ClinicalTrials.gov Identifier:	NCT00237835

Purpose

This study will compare the effects of newer atypical antipsychotics with those of older conventional antipsychotics on the risk of tardive dyskinesia.

Condition
Tardive Dyskinesia

Genetics Home Reference related topics: familial paroxysmal nonkinesigenic dyskinesia

U.S. FDA Resources

Study Type:	Observational
Study Design:	Natural History, Longitudinal, Defined Population, Prospective Study
Official Title:	Prevalence of Tardive Dyskinesia Among Patients Treated With Atypical Vs Conventional Antipsychotic

Further study details as provided by National Institute of Mental Health (NIMH):

Detailed Description:

We hypothesize that the newer atypical antipsychotics may not have lower risks of tardive dyskinesia compared to the older conventional antipsychotics.

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

patients at the Connecticut Mental Health Center receving antipsychotics

Exclusion Criteria:

severe neurological disease

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00237835

Sponsors and Collaborators

National Institute of Mental Health (NIMH)

Yale University

Investigators

Principal Investigator:

Scott W Woods, MD

Yale University

More Information

Study ID Numbers:	R01 MH61008, DSIR AT-SP
Study First Received:	October 7, 2005
Last Updated:	February 22, 2006
ClinicalTrials.gov Identifier:	NCT00237835
Health Authority:	United States: Federal Government

Study placed in the following topic categories:

Signs and Symptoms
Movement Disorders
Neurologic Manifestations
Central Nervous System Diseases

Dyskinesias
Tardive dyskinesia
Oral facial dyskinesia

Additional relevant MeSH terms:

Nervous System Diseases

ClinicalTrials.gov processed this record on January 16, 2009